PMID- 16102105
OWN - NLM
STAT- MEDLINE
DCOM- 20051130
LR  - 20230829
IS  - 1538-7933 (Print)
IS  - 1538-7836 (Linking)
VI  - 3
IP  - 9
DP  - 2005 Sep
TI  - Lupus anticoagulants and the risk of a first episode of deep venous thrombosis.
PG  - 1993-7
AB  - We have determined lupus anticoagulants, anti-beta2 glycoprotein I (beta2GPI) and 
      antiprothrombin antibodies in the Leiden Thrombophilia Study, a population-based 
      case-control study designed to determine risk factors for deep venous thrombosis 
      (DVT). Lupus anticoagulant (LAC) was measured in 473 patients and 472 control 
      subjects. Four control subjects (0.9%) and 14 patients (3.1%) had a positive LAC, 
      resulting in a 3.6-fold increased risk [odds ratio (OR) 3.6, 95% CI: 1.2-10.9]. 
      Of the total population, 49 were positive for anti-beta2GPI antibodies: 15 
      controls (3.4%) and 34 patients (7.5%), implying a 2.4-fold increased risk (95% 
      CI: 1.3-4.2). Antiprothrombin antibodies were present in 114 subjects: 48 
      controls (11.0%) and 66 cases (14.6%) with an OR of 1.4 (95% CI: 1.0-2.1). When 
      LAC was considered in the co-presence of antiprothrombin or anti-beta2GPI 
      antibodies the OR increased to 10.1 (95% CI: 1.3-79.8). A LAC without a positive 
      anti-beta2GPI or antiprothrombin test was not associated with a risk for DVT (OR 
      1.3, 95% CI: 0.3-6.0). This study demonstrates that the presence of LAC, 
      anti-beta2GPI antibodies and antiprothrombin antibodies are risk factors for DVT 
      in a general population. The strongest association holds for the combination LAC 
      and the presence of anti-beta2GPI or antiprothrombin antibodies.
FAU - de Groot, P G
AU  - de Groot PG
AD  - Department of Haematology, University Medical Center, Utrecht, The Netherlands. 
      ph.g.degroot@azu.nl
FAU - Lutters, B
AU  - Lutters B
FAU - Derksen, R H W M
AU  - Derksen RH
FAU - Lisman, T
AU  - Lisman T
FAU - Meijers, J C M
AU  - Meijers JC
FAU - Rosendaal, F R
AU  - Rosendaal FR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Thromb Haemost
JT  - Journal of thrombosis and haemostasis : JTH
JID - 101170508
RN  - 0 (Autoantibodies)
RN  - 0 (Glycoproteins)
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 9001-26-7 (Prothrombin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Autoantibodies/blood
MH  - Case-Control Studies
MH  - Female
MH  - Glycoproteins/immunology
MH  - Humans
MH  - Lupus Coagulation Inhibitor/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Prothrombin/immunology
MH  - Risk Factors
MH  - Venous Thrombosis/epidemiology/*etiology
MH  - beta 2-Glycoprotein I
EDAT- 2005/08/17 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/08/17 09:00
PHST- 2005/08/17 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/08/17 09:00 [entrez]
AID - S1538-7836(22)16167-2 [pii]
AID - 10.1111/j.1538-7836.2005.01485.x [doi]
PST - ppublish
SO  - J Thromb Haemost. 2005 Sep;3(9):1993-7. doi: 10.1111/j.1538-7836.2005.01485.x.